Amneal Pharmaceuticals (AMRX) Net Margin (2018 - 2026)

Amneal Pharmaceuticals' Net Margin history runs 9 years deep, the most recent figure standing at 10.8% for Q1 2026.

• In Q1 2026, Net Margin rose 726.0% year-over-year to 10.8%; the TTM figure through Mar 2026 stood at 5.95% (up 481.0% YoY), while the FY2025 annual figure was 4.24%, up 842.0% from the prior year.
• Net Margin was 10.8% for Q1 2026 at Amneal Pharmaceuticals, up from 6.09% in the prior quarter.
• In the past five years, Net Margin ranged from a high of 10.8% in Q1 2026 to a low of 74.34% in Q1 2022.
• Historically, Net Margin has averaged 5.49% across 5 years, with a median of 1.56% in 2023.
• The sharpest annual moves came in 2022 and 2023: Net Margin sank 7570 bps in 2022, then surged 7310 bps in 2023.
• A 5-year view of Net Margin shows it stood at 0.27% in 2022, then tumbled by 5940 bps to 15.99% in 2023, then surged by 82 bps to 2.84% in 2024, then jumped by 314 bps to 6.09% in 2025, then soared by 77 bps to 10.8% in 2026.
• The last three Net Margin figures came in at 10.8% (Q1 2026), 6.09% (Q4 2025), and 2.31% (Q3 2025), per Business Quant data.